Merck & Co. Inc. buy Finanzgonzo
Start price
28.07.11
/
50%
€24.30
Target price
09.01.12
€30.00
Performance (%)
26.55%
End price
09.01.12
€30.16
Summary
This prediction ended on 09.01.12 with a price of €30.16. The prediction had a final performance of 26.55%. Finanzgonzo has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Merck & Co. Inc. | 0.498% | 0.498% | 13.060% | 88.053% |
| iShares Core DAX® | 1.851% | 5.158% | 17.711% | 19.954% |
| iShares Nasdaq 100 | 1.573% | 2.589% | 39.053% | 56.636% |
| iShares Nikkei 225® | -0.412% | -2.857% | 13.501% | 7.721% |
| iShares S&P 500 | 1.128% | 2.485% | 29.871% | 47.507% |
Comments by Finanzgonzo for this prediction
In the thread Merck & Co. Inc. diskutieren
zulassung für victrelis in europa
Merck & Co hat die Zulassung für das Hepatitis C - Medikament Victrelis von der Europäischen Kommission erhalten. Kooperation mit Roche.
Quelle: Der Aktionär Nr. 31 / 2011
(Vom Mitglied beendet)